Novavax Global Commercial Operations and COVID-19 Vaccine Update

Commercial strategy in place to drive success in 2023+ Near-term priorities for commercial execution Competitive Product Label Expansion & Policy Recommendations Deliver bivalent or monovalent variant strain change vaccine in a competitive dose presentation for 2023 fall vaccination season • Expand label for heterologous boosting (adults and adolescents) and in younger children Achieve policy recommendations enabling broad market access Driving Brand Awareness • Educate healthcare professionals and consumers on Novavax and Nuvaxovid™, 1 novavax: 1. The trade name Nuvaxovid has not yet been approved by the FDA. © 2023 NOVAVAX. All rights reserved. 8

View entire presentation